Literature DB >> 19787805

Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study.

Anand Dutta1, Chandan Saha, Cynthia S Johnson, Naga Chalasani.   

Abstract

UNLABELLED: We conducted a study to characterize the variability in the upper limit of normal (ULN) for alanine aminotransferase (ALT) across different laboratories (labs) in Indiana and to understand factors leading to such variability. A survey was mailed to all eligible labs (n = 108) in Indiana, and the response rate was 62%. The survey queried for ALT ULN, the type of chemical analyzer used, five College of American Pathologists (CAP) sample results, and methods used to establish the reference interval. There was a wide variability in the ALT ULN for both men and women. Eighty-five percent of labs used chemical analyzers belonging to one of the four brands. For all five CAP samples, there was a statistically significant difference in ALT values measured by different analyzers (P < 0.0001), but these differences were not clinically significant. The majority of labs used the manufacturers' recommendations for establishing their ALT ULN rather than in-house healthy volunteer testing (only 17%). When healthy volunteers were tested, the process for testing was haphazard in terms of the number of individuals tested, frequency of testing, and criteria for choosing the reference population. After controlling for chemical analyzer type, there was no significant relationship between ALT ULN values and the method used for its establishment.
CONCLUSION: Wide variability in ALT ULN across different labs is more likely due to variable reference intervals of different chemical analyzers. It may be possible to minimize variability in ALT ULN by (1) each lab solely following the manufacturers' recommendations and (2) manufacturers of different analyzers following consistent and rigorous methodology in establishing the reference range. Alternatively, studies should be undertaken to identify outcome-based reference intervals for ALT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19787805     DOI: 10.1002/hep.23200

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

2.  How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.

Authors:  Varun Takyar; Anand Nath; Andrea Beri; Ahmed M Gharib; Yaron Rotman
Journal:  Hepatology       Date:  2017-07-27       Impact factor: 17.425

3.  Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study.

Authors:  Kali Zhou; Norah A Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2019-06-04       Impact factor: 11.382

4.  Upper limits of normal for alanine aminotransferase activity in the United States population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

5.  Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels.

Authors:  Bryce D Smith; Anthony K Yartel
Journal:  Am J Prev Med       Date:  2014-09       Impact factor: 5.043

6.  ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.

Authors:  Paul Y Kwo; Stanley M Cohen; Joseph K Lim
Journal:  Am J Gastroenterol       Date:  2016-12-20       Impact factor: 10.864

Review 7.  Perspectives on current controversial issues in the management of chronic HBV infection.

Authors:  Yun-Fan Liaw
Journal:  J Gastroenterol       Date:  2022-09-02       Impact factor: 6.772

Review 8.  Methodology to assess clinical liver safety data.

Authors:  Michael Merz; Kwan R Lee; Gerd A Kullak-Ublick; Andreas Brueckner; Paul B Watkins
Journal:  Drug Saf       Date:  2014-11       Impact factor: 5.606

9.  Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.

Authors:  Ulrike Schmid; Benjamin Weber; Celine Sarr; Matthias Freiwald
Journal:  BMC Pulm Med       Date:  2021-07-21       Impact factor: 3.317

10.  Serum aminotransferase levels in healthy population from western India.

Authors:  Satish Kumar; Anjali Amarapurkar; Deepak Amarapurkar
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.